PPARß/d: A Key Therapeutic Target in Metabolic Disorders.
Por:
Palomer FX, Barroso E, Pizarro J, Peña L, Botteri G, Zarei M, Aguilar D, Montori M and Vazquez M
Publicada:
20 mar 2018
Ahead of Print:
20 mar 2018
Resumen:
Research in recent years on peroxisome proliferator-activated receptor (PPAR)ß/d indicates that it plays a key role in the maintenance of energy homeostasis, both at the cellular level and within the organism as a whole. PPARß/d activation might help prevent the development of metabolic disorders, including obesity, dyslipidaemia, type 2 diabetes mellitus and non-alcoholic fatty liver disease. This review highlights research findings on the PPARß/d regulation of energy metabolism and the development of diseases related to altered cellular and body metabolism. It also describes the potential of the pharmacological activation of PPARß/d as a treatment for human metabolic disorders.
Filiaciones:
Palomer FX:
Pharmacology Unit, Department of Pharmacology, Toxicology and Therapeutic Chemistry, Institute of Biomedicine of the University of Barcelona (IBUB), Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain.
Pediatric Research Institute-Hospital Sant Joan de Déu, 08950 Esplugues de Llobregat, Spain.
Spanish Biomedical Research Center in Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, C/Monforte de Lemos 3-5, Pabellón 11, Planta 0, 28029 Madrid, Spain.
Open Access
|